#Switzerland #Basel #CordenPharma #peptides

CordenPharma Enters New Phase of Growth with Major Investment in Switzerland

In a bold move that signals its commitment to the future of peptide manufacturing, CordenPharma has announced a staggering investment of over 500 million euros for a new facility in the Basel region of Switzerland. This strategic initiative is part of a broader plan to invest more than 1 billion euros over the next three years in expanding its capabilities across Europe and the United States. With designs already laid out for a state-of-the-art manufacturing site in Getec Park, Muttenz, CordenPharma aims to establish itself as a leader in the supply of leading-edge peptide services.

Expansion Plans

The company’s latest venture comes after its announcement on July 16, 2024, regarding significant growth initiatives. This expansion is intended to bolster its peptide platform aimed at achieving over 1 billion euros in revenue by 2028. With the new plant in Switzerland, CordenPharma is keen to enhance its offerings for both injectable and oral peptide products.

Located just 8 kilometers from Basel, a well-regarded biotechnology and pharmaceutical hub in Europe, the site is strategically positioned to take advantage of existing infrastructure and logistics. Facilities for material handling are already in place, speeding up the process of bringing new products to market.

Infrastructure and Logistics

Investing in this new facility offers numerous logistical advantages:

• - Access to Transport: The facility will benefit from simplified access to various transport networks.
• - Established Utilities: Critical utilities required for chemical manufacturing are already available, ensuring smooth operational continuity.
• - Talent Pool: Being close to Basel provides access to a skilled workforce, essential for high-quality production processes.

Moreover, the production units will feature advanced technology, including solid-phase peptide synthesis (SPPS) reactors, which will cater to diverse peptide projects, such as GLP-1 and non-GLP-1 peptides. The expected total reactor capacity is projected to exceed 5,000 liters.

Economic Impact

This expansive new venture is expected to create over 300 new jobs in the region, showcasing CordenPharma's dedication to not just business expansion, but also to local economic growth and innovation. The primary construction phase is set to occur between 2025 and 2027, with commercial operations anticipated to commence in the first half of 2028.

Meanwhile, parallel expansions are in progress at CordenPharma’s Boulder, Colorado site, where enhancements to existing production lines and the construction of new facilities are already underway. This project will significantly enhance its capacity, with projections to more than double the current SPPS reactor capacity to over 42,000 liters by 2028.

Quotations from Leadership

Michael Quirmbach, CEO of CordenPharma, expressed enthusiasm regarding the project: "We are excited to announce the construction of a cutting-edge manufacturing facility just outside Basel, one of Europe's leading pharmaceutical and biotechnology centers. This new site is designed to allow flexible and efficient peptide manufacturing, addressing the increasing demand for innovative peptide-based therapeutics."

Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg, remarked on the significance of this expansion: "CordenPharma’s bold expansion reflects its leadership in addressing the rising demand for peptide manufacturing. Our commitment as a long-term investor is integral to this growth, combining industrial excellence with strategic investment to position CordenPharma as a leading global CDMO."

About CordenPharma

CordenPharma plays a pivotal role as a CDMO (Contract Development and Manufacturing Organization), aiding biotech and pharmaceutical innovators with complex modalities in drug development. With a global network of integrated facilities and expertise, the firm offers tailored outsourcing services from early-stage clinical development to commercialization. Following its acquisition by Astorg in 2022, CordenPharma is on a trajectory to enhance its growth and maintain its market leadership in peptide solutions.

To learn more about CordenPharma and its initiatives, visit CordenPharma's official website.